Indications——Cerebral edema due to ischemic stroke and other factors
(1) Cerebral edema is a common pathological injury secondary to brain diseases like cerebral stroke and cerebral trauma. B2067-1 targets the cellular physiological mechanism of cerebral edema to inhibit fluid imbalance due to osmotic pressure changes, thereby protecting brain cells from the source;
(2) B2067-1 is a new targeted monoclonal antibody, and there are no similar products on the globe yet;
(3) Existing treatment regimens for treatment of cerebral edema are all symptomatic, while B2067-1 offers protection for brain cells in the pathological setting through a completely new mechanism of action and is expected to radically reduce/minimize injuries secondary to brain diseases;
(4) In the treatment of cerebral edema after ischemic stroke, B2067-1 was found to be highly synergetic with our thrombolytic product PUK.
Next important events and time points
It is anticipated that preclinical pharmacodynamics, pharmacokinetics and safety evaluation studies will be initiated in the first quarter of 2022, and an IND application will be filed in the first quarter of 2023.